Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

ACE InhibitorsEnalapril2.5-10mg PO Q24-48HAdminister Post HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
3768811-2434-6050-601-2.438.8-4238-57 (low flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00584
  • Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010; 23(3):290-7.
  • Kelly J, Doyle G, Carmody M, Glover D, Cooper W. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. British journal of clinical pharmacology. 1988; 26(6):781-6.
  • Tsuruoka S, Kitoh Y, Kawaguchi A, et al. Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril. Journal of clinical pharmacology. 2007; 47(2):259-63.
  • Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007; 27(5):522-9.